Companies
MedChemExpress LLC (MCE)
Products
MedChemExpress - Model Cadonilimab - ...

MedChemExpress - Model Cadonilimab - 2394841-59-7

Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC)[1][2][3][4].

Cadonilimab

MCE China：Cadonilimab

Brand：MedChemExpress (MCE)

Cat. No.HY-P99117

CAS：2394841-59-7

Synonyms：AK104

Purity：99.29%

Storage：Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping：Shipping with dry ice.

Description：Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).

In Vitro：Cadonilimab (0-100 nM, 10-120 min) maintains a high affinity for Jurkat-CTLA4 and Jurkat-PD1 cells in vitro after iodine modification[4].

In Vivo：Cadonilimab (3.7 MBq, tail i.v., a single dose) modified with 124I largely enriches in the spleen, tumor sites and results in enrichment of PD1/CTLA4 positive immune cells at the tumor sites in humanized mice with MC38-hPD-L1 cell xenografts[4].

IC50 & Target：PD1[1] In Vitro Cadonilimab (0-100 nM, 10-120 min) maintains a high affinity for Jurkat-CTLA4 and Jurkat-PD1 cells in vitro after iodine modification[4]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Cadonilimab Related Antibodies

Species：Chimeric; Humanized

Isotype：Human IgG1 kappa

Recommend Isotype Controls：Human IgG1 kappa, Isotype Control

References：

[1]. Antonarelli G, et al. Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. Pharmaceuticals (Basel). 2021 Aug 31;14(9):884. [Content Brief]

[2]. Kaplon H, et al. Antibodies to watch in 2022. MAbs. 2022 Jan-Dec;14(1):2014296. [Content Brief]

[3]. Chen PY, et al. Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab. Front Immunol. 2023 Aug 3;14:1188523. [Content Brief]

[4]. Hou X, et al. Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice. Biomed Pharmacother. 2024 Jun;175:116669. [Content Brief]

Brand introduction:
•   MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world；
•   More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas；
•   The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects；
•   Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services；
•   It has a professional experimental center and strict quality control and verification system；
•   Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products；
•   The biological activity of the products has been verified by the experiments of customers in various countries；
•   A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers；
•   Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world；
•   It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。